IMCD Acquires Dong Yang FT to Expand in South Korean Beauty Sector

IMCD ito acquire Dong Yang FT to enhance its position in the beauty and personal care market in South Korea.

IMCD, a global partner for the distribution and formulation of speciality chemicals and ingredients, has signed an agreement to acquire 100% of the shares in Dong Yang FT.

Founded in 2009 and based in Seoul, South Korea, Dong Yang FT is a distributor of high-quality cosmetic ingredients, working with cosmetic manufacturers across the beauty and personal care sector. In 2024, Dong Yang FT reported revenues of KRW 55.3 billion (~€34 million).

The acquisition will help IMCD strengthen its presence in South Korea and broaden its product offering for the beauty and personal care markets. South Korea is one of the most innovative and largest beauty and personal care markets in the world, as well as a global exporter of beauty products and a recognized trendsetter. 


Dongjoon Lee, Managing Director of IMCD Korea and Seung-Ho Cha, Founder and CEO...
Dongjoon Lee, Managing Director of IMCD Korea and Seung-Ho Cha, Founder and CEO of Dong Yang FT
© IMCD

Dongjoon Lee, Managing Director of IMCD in South Korea, commented: “We are excited to welcome Dong Yang FT to our business. Their expertise, portfolio and strong technical and formulation know-how are a perfect fit with our strategy and will help us deliver solutions tailored to the highly globalized beauty market in South Korea, where innovation sets the pace. With this addition, we will be able to strengthen our position in South Korea and offer even more opportunities for growth to our teams, suppliers and customers.”

“This is an important milestone for us and a moment to thank our team for everything they have achieved so far,” said Seung-Ho Cha, Founder and CEO of Dong Yang FT. “We are proud of the trust we have built with customers and partners, and we are confident that joining IMCD will help us take this to the next level. With their global reach and resources, we can grow faster while staying true to the values that shaped our journey.”

The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2026.

Company

Logo:

IMCD Group B.V.

Wilhelminaplein 32
3072 Rotterdam
Netherlands

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.